Does the standard first-line treatment for PV increase risk of leukemia?
Who benefits most from this current CLL chemoimmunotherapy combo therapy?
The U.S. Food and Drug Administration has approved the use of the intravenous drug TRISENOX (Teva Pharmaceutical Industries Ltd.) in combination with tretinoin for first line treatment of adult patients who have been newly-diagnosed with low-risk APL.
A new study found that adverse effects were the most common reason for patients with chronic myeloid leukemia to discontinue use of tyrosine kinase inhibitors.
The U.S. Food and Drug Administration gave a green light to Novartis AG's leukemia treatment, marking the first time that a highly anticipated new type of potent gene-modifying immunotherapy has gained approval in the United States.
- Dabigatran anti-coagulation can now be reversed.
- FDA approves idarucizumab for reversal of dabigatran anti-coagulation.
- Normal coagulation is established “in minutes.”
- Preliminary data show idarucizumab to be safe and effective for reversal of dabigatran anti-coagulation.
- Both efficacy and safety trials are sponsored by the manufacturer and published in top-tier journals.